Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed

Next Previous
Trial Profile

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Rilpivirine (Primary) ; Antiretrovirals; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Proteasome inhibitors
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms SWORD-2
  • Sponsors ViiV Healthcare

Most Recent Events

  • 10 Nov 2023 Status changed from active, no longer recruiting to completed.
  • 05 Feb 2023 Results of pooled analysis from SWORD-1 and SWORD-2 assessing drug exposure and exposure-efficacy/safety relationships, published in the British Journal of Clinical Pharmacology
  • 26 Oct 2022 Results of pooled analysis assessing efficacy and safety (n=990; week 148) of switching to dolutegravir plus rilpivirine in virologically suppressed older populations living with HIV from SWORD-1 and SWORD-2 studies, presented at the 16th International Congress on Drug Therapy and HIV Infection.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top